Citizens JMP downgraded Rallybio (RLYB) to Market Perform from Outperform without a price target after the company discontinued development of its fetal and neonatal alloimmune thrombocytopenia program after missing the pharmacokinetic profile in the sentinel pregnant woman dosed with RLYB212. The firm downgraded the shares after removing RLYB212 from its valuation. Citizens says RLYB212 was the basis of its Outperform rating. It now expects the shares to continue to trade at a “steep discount” to Rallybio’s cash balance. The stock in afternoon trading is down 41%, or 17c, to 25c.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB:
- Rallybio downgraded to Market Perform from Outperform at Citizens JMP
- Rallybio discontinues RLYB212 program
- Rallybio’s Promising Developments and Financial Stability Justify Buy Rating
- Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating
- Rallybio Corporation Reports 2024 Financial Results and Progress